{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T22:23:21Z","timestamp":1757456601749,"version":"3.40.5"},"reference-count":41,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,8,1]],"date-time":"2014-08-01T00:00:00Z","timestamp":1406851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","thrombosisresearch.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1016\/j.thromres.2014.06.006","type":"journal-article","created":{"date-parts":[[2014,6,16]],"date-time":"2014-06-16T19:54:04Z","timestamp":1402948444000},"page":"526-530","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Tissue factor pathway inhibitor and thrombin-activatable carboxypeptidase B for prediction of early atherosclerosis in gouty arthritis"],"prefix":"10.1016","volume":"134","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7359-387X","authenticated-orcid":false,"given":"Mehmet Sevki","family":"Uyanik","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gulsum Emel","family":"Pamuk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omer Nuri","family":"Pamuk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sedat Alpaslan","family":"Tuncel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.thromres.2014.06.006_bb0005","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1002\/art.1780130408","article-title":"A historical note: Leeuwenhoek's description of crystals from a gouty tophus","volume":"13","author":"McCarty","year":"1970","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.thromres.2014.06.006_bb0010","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1016\/j.amjmed.2008.06.014","article-title":"Role of inflammation in atherosclerosis associated with rheumatoid arthritis","volume":"121","author":"Libby","year":"2008","journal-title":"Am J Med"},{"key":"10.1016\/j.thromres.2014.06.006_bb0015","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1002\/1529-0131(199902)42:2<338::AID-ANR17>3.0.CO;2-U","article-title":"Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus","volume":"42","author":"Ward","year":"1999","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.thromres.2014.06.006_bb0020","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.amjmed.2008.06.010","article-title":"Subclinical atherosclerosis in rheumatoid arthritis and systemic lupus erythematosus","volume":"121","author":"Salmon","year":"2008","journal-title":"Am J Med"},{"key":"10.1016\/j.thromres.2014.06.006_bb0025","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1161\/01.HYP.0000150785.39055.e8","article-title":"Resurrection of uric acid as a causal risk factor in essential hypertension","volume":"45","author":"Johnson","year":"2005","journal-title":"Hypertension"},{"key":"10.1016\/j.thromres.2014.06.006_bb0030","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1161\/CIRCULATIONAHA.107.703389","article-title":"Independent impact of gout on mortality and risk for coronary heart disease","volume":"116","author":"Choi","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.thromres.2014.06.006_bb0035","doi-asserted-by":"crossref","first-page":"7","DOI":"10.7326\/0003-4819-131-1-199907060-00003","article-title":"Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study","volume":"131","author":"Culleton","year":"1999","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.thromres.2014.06.006_bb0040","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1002\/art.22014","article-title":"Gout and the risk of acute myocardial infarction","volume":"54","author":"Krishnan","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.thromres.2014.06.006_bb0045","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/0895-4356(88)90127-8","article-title":"Gout and coronary heart disease: the Framingham Study","volume":"41","author":"Abbott","year":"1988","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.thromres.2014.06.006_bb0050","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1093\/fampra\/cmg413","article-title":"Gout, just a nasty event or a cardiovascular signal? A study from primary care","volume":"20","author":"Janssens","year":"2003","journal-title":"Fam Pract"},{"key":"10.1016\/j.thromres.2014.06.006_bb0055","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.1161\/01.CIR.0000099844.31524.05","article-title":"Explaining how \"high-grade\" systemic inflammation accelerates vascular risk in rheumatoid arthritis","volume":"108","author":"Sattar","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.thromres.2014.06.006_bb0060","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1136\/ard.52.9.643","article-title":"Abnormal plasma fibrinolysis in patients with rheumatoid arthritis and impaired endothelial fibrinolytic response in those complicated by vasculitis","volume":"52","author":"Lau","year":"1993","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.thromres.2014.06.006_bb0065","doi-asserted-by":"crossref","first-page":"R158","DOI":"10.1186\/ar3116","article-title":"Atherosclerosis in early rheumatoid arthritis: very early endothelial activation and rapid progression of intima media thickness","volume":"12","author":"Sodergren","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.thromres.2014.06.006_bb0070","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1007\/s00296-003-0324-1","article-title":"Plasminogen activator inhibitor-1 as a link between pathological fibrinolysis and arthritis of Behcet's disease","volume":"24","author":"Ozturk","year":"2004","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.thromres.2014.06.006_bb0075","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/ajh.2830370104","article-title":"Disturbances in the tissue plasminogen activator\/plasminogen activator inhibitor (TPA\/PAI) system in systemic lupus erythematosus","volume":"37","author":"Ruiz-Arguelles","year":"1991","journal-title":"Am J Hematol"},{"key":"10.1016\/j.thromres.2014.06.006_bb0080","first-page":"95","article-title":"Thrombomodulin, tissue plasminogen activator and plasminogen activator inhibitor-1 in Henoch-Schonlein purpura","volume":"16","author":"Besbas","year":"1998","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.thromres.2014.06.006_bb0085","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1093\/rheumatology\/36.10.1045","article-title":"The coagulation\/fibrinolysis balance in systemic sclerosis: evidence for a haematological stress syndrome","volume":"36","author":"Ames","year":"1997","journal-title":"Br J Rheumatol"},{"key":"10.1016\/j.thromres.2014.06.006_bb0090","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1111\/j.1538-7836.2008.03249.x","article-title":"The activation peptide of thrombin-activatable fibrinolysis inhibitor: a role in activity and stability of the enzyme?","volume":"7","author":"Marx","year":"2009","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.thromres.2014.06.006_bb0095","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1055\/s-0030-1265293","article-title":"Tissue factor and tissue factor pathway inhibitor as key regulators of global hemostasis: measurement of their levels in coagulation assays","volume":"36","author":"Kasthuri","year":"2010","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.thromres.2014.06.006_bb0100","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.atherosclerosis.2009.04.024","article-title":"Tissue factor pathway inhibitor, vascular risk factors and subclinical atherosclerosis: the Multi-Ethnic Study of Atherosclerosis","volume":"207","author":"Mitchell","year":"2009","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.thromres.2014.06.006_bb0105","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1002\/art.10869","article-title":"Role of the tissue factor pathway in synovial inflammation","volume":"48","author":"Busso","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.thromres.2014.06.006_bb0110","doi-asserted-by":"crossref","first-page":"262","DOI":"10.2741\/3926","article-title":"Tissue factor pathway inhibitor: structure-function","volume":"17","author":"Broze","year":"2012","journal-title":"Front Biosci"},{"key":"10.1016\/j.thromres.2014.06.006_bb0115","doi-asserted-by":"crossref","first-page":"4080","DOI":"10.1016\/j.molimm.2008.07.010","article-title":"Regulation of tissue inflammation by thrombin-activatable carboxypeptidase B (or TAFI)","volume":"45","author":"Leung","year":"2008","journal-title":"Mol Immunol"},{"key":"10.1016\/j.thromres.2014.06.006_bb0120","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1007\/s00296-011-1900-4","article-title":"Subclinical atherosclerosis in gouty arthritis patients: a comparative study","volume":"32","author":"Cukurova","year":"2012","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.thromres.2014.06.006_bb0125","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1002\/art.1780200320","article-title":"Preliminary criteria for the classification of the acute arthritis of primary gout","volume":"20","author":"Wallace","year":"1977","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.thromres.2014.06.006_bb0130","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1161\/01.HYP.0000107251.49515.c2","article-title":"Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure","volume":"42","author":"Chobanian","year":"2003","journal-title":"Hypertension"},{"key":"10.1016\/j.thromres.2014.06.006_bb0135","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1007\/s00125-012-2534-0","article-title":"Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"55","author":"Inzucchi","year":"2012","journal-title":"Diabetologia"},{"key":"10.1016\/j.thromres.2014.06.006_bb0140","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.atherosclerosis.2008.05.022","article-title":"Uric acid: A marker of increased cardiovascular risk","volume":"202","author":"Gagliardi","year":"2009","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.thromres.2014.06.006_bb0145","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1073\/pnas.86.8.2839","article-title":"Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque","volume":"86","author":"Wilcox","year":"1989","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.thromres.2014.06.006_bb0150","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.blre.2013.03.001","article-title":"The role of tissue factor pathway inhibitor in atherosclerosis and arterial thrombosis","volume":"27","author":"Winckers","year":"2013","journal-title":"Blood Rev"},{"key":"10.1016\/j.thromres.2014.06.006_bb0155","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1097\/00001721-199507000-00004","article-title":"Blocking of tissue factor pathway inhibitor (TFPI) shortens the bleeding time in rabbits with antibody induced haemophilia A","volume":"6","author":"Erhardtsen","year":"1995","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.thromres.2014.06.006_bb0160","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1055\/s-0038-1646439","article-title":"Inhibition of extrinsic pathway inhibitor shortens the coagulation time of normal plasma and of hemophilia plasma","volume":"66","author":"Nordfang","year":"1991","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.thromres.2014.06.006_bb0165","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1042\/cs1010093","article-title":"Effects of combined oral hormone replacement therapy on tissue factor pathway inhibitor and factor VII","volume":"101","author":"Peverill","year":"2001","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.thromres.2014.06.006_bb0170","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1002\/(SICI)1096-8652(199903)60:3<175::AID-AJH1>3.0.CO;2-X","article-title":"Decreased plasma tissue factor pathway inhibitor in women taking combined oral contraceptives","volume":"60","author":"Harris","year":"1999","journal-title":"Am J Hematol"},{"key":"10.1016\/j.thromres.2014.06.006_bb0175","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1111\/j.1538-7836.2006.01873.x","article-title":"A GPI-anchored co-receptor for tissue factor pathway inhibitor controls its intracellular trafficking and cell surface expression","volume":"4","author":"Maroney","year":"2006","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.thromres.2014.06.006_bb0180","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1160\/TH10-02-0091","article-title":"Thrombin generation in rheumatoid arthritis: dependence on plasma factor composition","volume":"104","author":"Undas","year":"2010","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.thromres.2014.06.006_bb0185","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1177\/0961203311418267","article-title":"Impaired control of the tissue factor pathway of blood coagulation in systemic lupus erythematosus","volume":"20","author":"Adams","year":"2011","journal-title":"Lupus"},{"key":"10.1016\/j.thromres.2014.06.006_bb0190","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1002\/ajh.1186","article-title":"Increased levels of tissue factor pathway inhibitor may reflect disease activity and play a role in thrombotic tendency in Behcet's disease","volume":"68","author":"Akarsu","year":"2001","journal-title":"Am J Hematol"},{"key":"10.1016\/j.thromres.2014.06.006_bb0195","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.thromres.2013.09.017","article-title":"Ambivalent roles of carboxypeptidase B in the lytic susceptibility of fibrin","volume":"133","author":"Kovacs","year":"2014","journal-title":"Thromb Res"},{"key":"10.1016\/j.thromres.2014.06.006_bb0200","doi-asserted-by":"crossref","first-page":"3951","DOI":"10.1007\/s00296-011-2279-y","article-title":"PAI-1 mRNA expression and plasma level in rheumatoid arthritis: relationship with 4G\/5G PAI-1 polymorphism","volume":"32","author":"Munoz-Valle","year":"2012","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.thromres.2014.06.006_bb0205","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.thromres.2013.10.034","article-title":"Thrombin activatable fibrinolysis inhibitor (TAFI): more complex when it meets the clot","volume":"133","author":"Philippou","year":"2014","journal-title":"Thromb Res"}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384814003314?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384814003314?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,11]],"date-time":"2019-08-11T11:41:19Z","timestamp":1565523679000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384814003314"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["S0049384814003314"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2014.06.006","relation":{},"ISSN":["0049-3848"],"issn-type":[{"type":"print","value":"0049-3848"}],"subject":[],"published":{"date-parts":[[2014,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tissue factor pathway inhibitor and thrombin-activatable carboxypeptidase B for prediction of early atherosclerosis in gouty arthritis","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2014.06.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}